Market News & Trends
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application
Biogen and Eisai, Co., Ltd. recently announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the…
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership
Taysha Gene Therapies Inc. and Catalent recently announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy…
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial
Rubius Therapeutics, Inc. recently announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of…
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation
Orchard Therapeutics recently announced the presentation of new clinical data at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting to be held virtually…
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials for the Treatment of Parkinson’s Disease
Cerevel Therapeutics recently announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon…
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies
Aerogen recently announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and…
Catalent to Acquire Cell Therapy Manufacturing Facility From Bone Therapeutics
Catalent recently announced it had signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including…
XOMA Earns $25-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25-million milestone payment…
Taconic Biosciences Launches Critical Model for COVID-19 Research
Taconic Biosciences recently announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter…
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate
Orasis Pharmaceuticals recently announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the US, evaluating its novel eye drop candidate designed to…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….